CDSCO panel tells Glenmark to submit complete clinical trial report on antidiabetic FDC Drug

Published On 2022-09-24 12:13 GMT   |   Update On 2022-09-24 12:13 GMT
Advertisement

In response to drug major Glenmark proposal to manufacture and market the antidiabetic fixed dose combination Lobeglitazone Sulphate 0.5/0.5mg plus Metformin HCL 500/1000mg ER tablets, the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has recommended Glenmark to submit the complete clinical trial report.

This came after the drug maker Glenmark presented their proposal for manufacturing and marketing of Lobeglitazone Sulphate 0.5/0.5mg plus Metformin HCL 500/1000mg ER tablets along with safety efficacy and safety data.

For more details, check out the link given below:

Submit Complete CT Report :CDSCO Tells Glenmark On Antidiabetic FDC Drug


Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News